Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
House Dust Mite SLIT Tablet in Allergic Rhinitis/Rhinoconjunctivitis (China EEC Study)
CTR20191481Phase 3Terminated
- Sponsor
- ALK-Abelló
- Start
- Aug 2019
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of House dust mite allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), asthma, sponsored by ALK-Abelló. Started Aug 2019; status: terminated.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on CTR20191481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191481.